Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
详细信息 查看全文
- 作者：Ruben Mesa ; Srdan Verstovsek ; Jean-Jacques Kiladjian ; Martin Griesshammer ; Tamas Masszi ; Simon Durrant ; Francesco Passamonti ; Claire N. Harrison ; Fabrizio Pane ; Pierre Zachee ; Huiling Zhen ; Mark M. Jones ; Shreekant Parasuraman ; Jingjin Li ; Isabelle Cô ; té ; Dany Habr and Alessandro M. Vannucchi
- 刊名：European Journal of Haematology
- 出版年：2016
- 出版时间：August 2016
- 年：2016
- 卷：97
- 期：2
- 页码：192-200
- 全文大小：575K
- ISSN：1600-0609
文摘
Polycythemia vera (PV)-related symptoms may not be adequately controlled with conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of ruxolitinib compared with standard therapy on quality of life (QoL) and symptoms in patients with PV who were hydroxyurea resistant/intolerant.